Abstract: Methods of sequestering carbon dioxide (CO2) are provided. Aspects of the methods include precipitating a storage stable carbon dioxide sequestering product from an alkaline-earth-metal-containing water and then disposing of the product, e.g., by placing the product in a disposal location or using the product as a component of a manufactured composition. Also provided are systems for practicing methods of the invention.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Abstract: A system and method of providing and validating a bar-code on a lottery ticket to allow secure verification of tickets is described. Lottery ticket information comprising unique identifying information uniquely identifying the lottery ticket and validation information for use in determining a prize value associated with the lottery ticket is generated. First redundancy information is generated using the validation information and a portion of the unique identifying information. The first redundancy information used for checking the integrity of subsequently received validation information. The validation information is encrypted and second redundancy information is generated using the unique identifying information and the encrypted validation information. A first bar-code is constructed using the unique identifying information, the encrypted validation information and the second redundancy information.

Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

Abstract: A holder for a telecommunications device includes a container including a side wall connected to a base. Together the side wall and base define a cavity. Side wall defines an opening of the container at an end of the side wall distal to the base. A resilient insert is disposed inside the cavity. The insert includes a bottom portion that abuts the base and a feature for releasably retaining the device inside the container. A lid is in selective locking engagement with the side wall's distal end. When in locking engagement, the lid encloses the opening of the container to retain the device inside the holder, and to muffle a sound and/or a vibration produced by the device. A locking mechanism is operatively attached to the container and/or the lid, and holds the lid and the container together when the lid is in locking engagement with the distal end.

Abstract: Reduced-carbon footprint compositions, and methods for making and using the same, are provided. Aspects of the reduced-carbon footprint compositions include producing carbonate compositions from CO2, which compositions may replace conventional hydraulic cement and/or aggregate components of the compositions. The reduced-carbon footprint compositions find use in a variety of applications, including use in a variety of building materials and building applications.

Abstract: The disclosed invention provides for the treatment of pancreatitis, and the alleviation of pain associated therewith, with amylin, amylin agonists and amylin analogs.

Abstract: Provided herein are cementitious compositions including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Such compositions may be made from carbonate brines. Methods and systems for making the compositions and using the compositions are also provided.

Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.

Abstract: Reduced-carbon footprint concrete compositions, and methods for making and using the same, are provided. Aspects of the reduced-carbon footprint concrete compositions include CO2-sequestering carbonate compounds, which may be present in the hydraulic cement and/or aggregate components of the concrete. The reduced-carbon footprint concrete compositions find use in a variety of applications, including use in a variety of building materials and building applications.

Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.

Abstract: CO2-sequestering formed building materials are provided. The building materials of the invention include a composition comprising a carbonate/bicarbonate component. Additional aspects of the invention include methods of making and using the CO2-sequestering formed building material.

Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

Abstract: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.

Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

Abstract: Non-cementitious CO2 sequestering compositions are provided. The compositions of the invention include a CO2 sequestering additive, e.g., a CO2 sequestering carbonate composition. Additional aspects of the invention include methods of making and using the non-cementitious CO2 sequestering compositions.

Abstract: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.

Abstract: CO2-sequestering formed building materials are provided. The building materials of the invention include a composition comprising a carbonate/bicarbonate component. Additional aspects of the invention include methods of making and using the CO2-sequestering formed building material.

Abstract: A gastrointestinal implant device is positioned in a patient's small intestine or rectum and produces an outward force that itself produces a distension signal which is a therapeutically useful neural or humoral signal that evokes satiogenic or weight loss effects by itself. The device may advantageously be placed in the duodenum adjacent the pylorus or in the jejunum, ileum or rectum. The distension signals may amplify chemosensory or mechanosensory signals such as enteroendocrine secretions within the patient. The device may be a mesh and include a low material density that allows for unrestricted chyme absorption within the small intestine and unrestricted chyme flow through the gastrointestinal system. A method includes inserting the device into the patient then either retrieving the device after treatment is complete or allowing a device formed of a biodegradable material to degrade in time after treatment is complete.

Abstract: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.